Reaction
Facial Discomfort reporting signals
As of the last recalculation, Facial Discomfort appears in 655 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is BOTULINUM TOXIN TYPE A (PRR 80.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Botulinum Toxin Type A | 30 | 80.4 | 80.6 |
| Onabotulinumtoxina | 56 | 25.1 | 25.1 |
| Cenegermin-Bkbj | 8 | 21.3 | 21.3 |
| Cladribine | 5 | 16.7 | 16.7 |
| Inclisiran | 3 | 11.9 | 11.9 |
| Eptinezumab-Jjmr | 3 | 10.5 | 10.5 |
| Rimegepant Sulfate | 4 | 10.1 | 10.1 |
| Crisaborole | 3 | 10.0 | 10.0 |
| Dupilumab | 119 | 9.4 | 9.4 |
| Ofatumumab | 9 | 8.7 | 8.7 |